tirzepatide lilly Shows Superiority in SURMOUNT-3 and 4 FDA approves tirzepatide, Eli Lilly's

Increase insulin production Reduces food intake by lowering appetite Slows food digestion in the stomach Weight loss Improved cardiometabolic measures A1C Production

Steins M, Thomas M, Geissler M

(2025, January 30)

Published clinical trials used continuous daily administration for 12-24 weeks without scheduled breaks, establishing this as a viable approach with maintained safety throughout the treatment period

Eli Lilly and Company has announced positive topline results for the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase III trial